Lindahl provides an update on difficult position for orphan drugs

Lindahl provides an update on difficult position for orphan drugs

Dela med dig av vår kunskap
Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedInEmail this to someone

In the latest newsletter from the International Law Office, Lindahl’s Annie Kabala and Jonas Löfgren provides an update on recent developments in Sweden regarding the use of products that are not approved for the same indication (off-label use) as comparator to new medicinal products in pricing decisions.

Read the article here

Also read: Orphan drug denied reimbursement in health technology assessment

Annie Kabala

annie.kabala@lindahl.se